Drugs / Lumiliximab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00058396 | Oct 2002 → Oct 2004 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00046488 | Sep 2002 → Apr 2004 | B-cell chronic lymphocytic leukemia | Biogen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00103558 | Mar 2004 → Jan 2010 | B-cell chronic lymphocytic leukemia | Biogen | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00801060 | Feb 2008 → Jun 2010 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00391066 | Nov 2006 → Jul 2010 | B-cell chronic lymphocytic leukemia | Biogen | Terminated | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lumiliximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00391066 ↗ |
| Known as | Gomiliximab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109151 ↗ |
| Known as | IDEC-152 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00046488 ↗ |
| Known as | P5E8 SI-3401 GOMILIXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109151 ↗ |
| Known as | Primatized anti-cd23 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109151 ↗ |
| Known as | ST-152 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109151 ↗ |
| Action | Inhibit | “Immunoglobulin epsilon Fc receptor antagonist” CHEMBL2109151 ↗ |
| Modality | Monoclonal antibody | “anti-CD23 monoclonal antibody” PMID 19843887 ↗ Oct 2009 |
| Target | FCER2 | “Immunoglobulin epsilon Fc receptor antagonist” CHEMBL2109151 ↗ |